<DOC>
	<DOCNO>NCT00543205</DOCNO>
	<brief_summary>This open-label , parallel-group study total 16 evaluable subject . Subjects assign 1 follow cohort : Cohorts I ( subject normal hepatic function ; n+8 Cohort II ( subject moderate hepatic impairment , Child-Pugh classification Grade B ; n=8 ) . If , reason , Genasense infusion interrupt discontinue prior completion rate administration Genasense infusion change , subject replace .</brief_summary>
	<brief_title>Pharmacokinetics G3139 Subjects With Advanced Melanoma , Including Those With Normal Hepatic Function Those With Moderate Hepatic Impairment</brief_title>
	<detailed_description />
	<mesh_term>Melanoma</mesh_term>
	<criteria>Histologically confirm diagnosis malignant melanoma Metastatic Stage IV disease , Stage III disease surgically resectable ECOG Performance status 0,1 , 2 Adequate venous access Agreement practice effective method birth control Hepatically impair consistent ChildPugh classification Grade B Chronic intravascular coagulopathy confirm presence fibrinogen degradation product , metastasis liver , exudative ascites Prior organ allograft Requirement concomitant anticoagulant therapy ( exception 1 mg/day warfarin central line prophylaxis ) receive protocol therapy Known hypersensitive DTIC Prior treatment Genasense</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2009</verification_date>
</DOC>